Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 257

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 257
---
 
     12.14  
     - 
  
    Net Revenue (Loss) 
     48.81  
     (87.15)

    Operating Expenses: 

    Research and Development 
     820.73  
     272.81 
  
    General and Administrative Expenses 
     827.06  
     1,672.83 
  
    Total Operating Expenses 
     1,647.78  
     1,945.64 

    Loss from Operations 
     (1,598.97) 
     (2,032.78)

    Interest Expense 
     (1.30) 
     (901.77)
  
    Derivative Expense 
     -  
     (157.64)
  
    Change in Fair Value of Derivative Liabilities 
     274.20  
     (14.70)
  
    Loss on Debt Extinguishment 
     -  
     (485.65)
  
    Change in Fair Value of Promissory Note 
     -  
     2,121.39 
  
    Other Income (Expense), net 
     16.70  
     (32.78)
  
    Total Interest and Other Income (Expense), net 
     289.60  
     528.85 
  
    Loss from Operations before Provision for Income Taxes 
     (1,309.37) 
     (1,503.93)
  
    Provision for Income Taxes (Note 9) 
     0.04  
     0.10 
  
    Net Loss including Noncontrolling Interest 
     (1,309.41) 
     (1,504.02)
  
    Net Loss – Noncontrolling Interest 
     (1.41) 
     (18.97)
  
    Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. 
     (1,308.01)% 
     (1,485.06)%

4. Comparison of the Years Ended December
31, 2024, and 2023

Product Revenues - net of Discounts and Rebates, Cost of Revenues,
Gross Profit (Loss), and Gross Margin

    For the Year Ended
    December 31,  

    Consolidated Statements of Operations Data: 
    2024  
    2023